Research Grade Biosimilars Antibodies
Absolute Antibody provides a range of research-grade biosimilar antibodies, including Trastuzumab, Gemtuzumab, Rituximab, Infliximab, Daclizumab, Basiliximab, Cetuximab, and Eculizumab. Each biosimilar is available in the original human format and can also be customized with a mouse, rabbit, rhesus monkey, or cynomolgus monkey constant domain.
Place your order directly with the manufacturer.
Absolute Antibody research-grade biosimilar antibodies can be used as controls to benchmark novel biotherapeutics (biologics) for pre-clinical lead identification and for the development of potency assays. Each biosimilar antibody is supplied in PBS buffer with preservative and adheres to the following specifications:
- Endotoxin is < 1.0 EU/mg as determined by the LAL method
- Purity is > 96% as determined by SDS-PAGE
CONJUmAbs research-grade biosimilar antibodies from Absolute Antibody are carrier free products specifically designed for Antibody Drug Conjugate research. These concentrated, high purity, and low endotoxin antibodies are formulated to make your conjugation procedure easier. Trastuzumab, Gemtuzumab, and Cetuximab can be purchased off-the-shelf, with other CONJUmAbs biosimilar antibodies available upon request.
- Concentrated – 5 mg/ml concentration eliminates the need to concentrate before conjugation
- High Purity – Additional purification step results in > 99% purity and > 98% monomer by SEC-HPLC
- Low Endotoxin – < 0.5 EU/mg endotoxin suitable for in vivo and in vitro use
- Carrier Free – Formulated without the use of Proclin 300, sodium azide, BSA, and other excipients
Absolute Antibody research-grade biosimilars are NOT FOR THERAPEUTIC USE.
Bispecific ADCs targeting the cancer, not the patient
Tuesday, July 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Bispecific antibody-drug conjugates (ADCs) represent an emerging frontier in targeted cancer therapy, combining the precision of antibody-based targeting with the potency of cytotoxic payloads. By recognizing two distinct tumor-associated markers rather than one, bispecific ADCs can improve tumor selectivity, helping to distinguish cancer cells from healthy tissue and potentially reducing off-target effects. As the field advances, researchers are exploring innovative approaches to address longstanding challenges in efficacy, safety, and patient outcomes, making bispecific ADCs a rapidly growing area of interest in oncology research and drug development.
This SelectScience webinar introduces BiVictriX Therapeutics and its role as an early pioneer in bispecific, logic gated, ADCs. It will cover how ADCs are reshaping targeted cancer therapy and why bispecific targeting offers a route to improved tumor selectivity and reduced off-tumor toxicity. The presentation will also explore the key steps to take when designing a bispecific ADC, including target selection, antibody format, linker strategy, and payload choice, and how these decisions influence efficacy, safety, and clinical potential.
Antibody expertise and bespoke reagents elevate life sciences research
See how Life Science Group and Absolute Antibody partner to deliver a flexible antibody offering for future-focused life sciences research
